SGLT2 inhibitors improve cardiovascular and renal outcomes in patients with cardiovascular disease (CVD) and heart failure (HF), regardless of ejection fraction or the presence of type 2 diabetes (T2D). Here, SLC5A2 is linked to type 2 diabetes mellitus.